
TARS
Tarsus Pharmaceuticals Inc.
$55.63
+$0.63(+1.15%)
40
Overall
--
Value
40
Tech
--
Quality
Market Cap
$2.32B
Volume
721.72K
52W Range
$31.36 - $59.76
Target Price
$74.57
Order:
Income Statement
Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|
REVENUE | |||||||
Total Revenue | -- | $57.0M | $25.8M | $17.4M | $183.0M | ||
Total Revenue | -- | $57.0M | $25.8M | $17.4M | $183.0M | ||
COST OF GOODS SOLD | |||||||
Cost of Revenue | -- | $2.1M | $955.0K | -- | -- | ||
GROSS PROFIT | |||||||
Gross Profit | -- | $55.0M | $24.9M | $15.9M | $170.1M | ||
OPERATING EXPENSES | |||||||
Operating Expenses | $27.0M | $69.2M | $87.6M | $159.0M | $290.7M | ||
Research & Development | $18.8M | $41.7M | $42.6M | $50.3M | $53.4M | ||
Research Expense | $18.8M | $41.7M | $42.6M | $50.3M | $53.4M | ||
Selling, General & Administrative | $8.2M | $27.5M | $44.9M | $108.7M | $237.3M | ||
Selling & Marketing Expenses | -- | -- | -- | $9.4M | $29.8M | ||
General & Administrative Expenses | $8.2M | $27.5M | $44.9M | $108.7M | $237.3M | ||
Depreciation & Amortization | $100.0K | $300.0K | $325.0K | $744.0K | $685.0K | ||
Depreciation & Amortization | $100.0K | $300.0K | $325.0K | -- | -- | ||
Amortization | -- | -- | $174.0K | $4.1M | $8.7M | ||
Other Operating Expenses | $-217.0K | $645.0K | $813.0K | -- | -- | ||
OPERATING INCOME | |||||||
Operating income | $-27.0M | $-12.2M | $-62.7M | $-143.2M | $-120.6M | ||
EBITDA | $-26.9M | $-13.5M | $-59.7M | $-131.8M | $-106.9M | ||
NON-OPERATING ITEMS | |||||||
Interest Expense (Non-Operating) | -- | -- | $2.1M | $3.3M | $7.8M | ||
Intinc | $188.0K | $36.0K | $3.5M | $10.3M | $15.0M | ||
Net Non-Operating Interest Income/Expense | $188.0K | $36.0K | $1.3M | $7.0M | $7.2M | ||
Gain on Sale of Securities | -- | $-987.0K | $-501.0K | $376.0K | $-792.0K | ||
Other Income/Expense | $15.0K | $1.7M | $-683.0K | $-274.0K | $2.1M | ||
Other Special Charges | -- | $-73.0K | $86.0K | $-102.0K | $-1.4M | ||
SPECIAL ITEMS | |||||||
Special Income Charges | -- | -- | $-955.0K | -- | -- | ||
Other Impairment Of Capital Assets | $15.0K | $2.0K | -- | -- | -- | ||
PRE-TAX INCOME | |||||||
EBIT | $-27.0M | $-13.8M | $-60.0M | $-132.7M | $-108.1M | ||
Pre-Tax Income | $-26.8M | $-13.8M | $-62.1M | $-135.9M | $-115.6M | ||
INCOME TAX | |||||||
Tax Provision | $1.0K | $55.0K | $-4.0K | $-4.4M | $-4.3M | ||
NET INCOME | |||||||
Net Income | $-26.8M | $-13.8M | $-62.1M | $-135.9M | $-115.6M | ||
Net Income (Continuing Operations) | $-26.8M | $-13.8M | $-62.1M | $-135.9M | $-115.6M | ||
Net Income (Discontinued Operations) | $-26.8M | $-13.8M | $-62.1M | $-135.9M | $-115.6M | ||
Net Income (Common Stockholders) | $-26.8M | $-13.8M | $-62.1M | $-135.9M | $-115.6M | ||
Normalized Income | -- | -- | -- | -- | $-119.8M | ||
TOTALS | |||||||
Total Expenses | $27.0M | $71.3M | $88.5M | $159.0M | $290.7M | ||
SHARE & EPS DATA | |||||||
Average Shares Outstanding | $6.2M | $20.6M | $24.6M | $29.4M | $37.6M | ||
Average Shares Outstanding (Diluted) | -- | $20.6M | $24.6M | $29.4M | $37.6M | ||
Shares Outstanding | $20.5M | $20.7M | $26.7M | $34.2M | $38.4M | ||
Basic EPS | $-4.32 | $-0.67 | $-2.52 | $-4.62 | $-3.07 | ||
Basic EPS (Continuing Operations) | $-4.32 | $-0.67 | $-2.52 | $-4.62 | $-3.07 | ||
Diluted EPS | $-4.32 | $-0.67 | $-2.52 | $-4.62 | $-3.07 | ||
Diluted EPS (Continuing Operations) | -- | $-0.67 | $-2.52 | $-4.62 | $-3.07 | ||
OTHER METRICS | |||||||
Interest Expense Operating | -- | -- | $1.9M | -- | -- | ||
Other Gand A | $8.2M | $27.5M | $44.9M | $108.7M | $237.3M | ||
Rent And Landing Fees | -- | $2.1M | -- | -- | -- | ||
Write Off | -- | -- | $955.0K | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | TARS | $55.63 | +1.1% | 721.72K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Tarsus Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW